News & Updates

Palbociclib combined with endocrine therapy (ET) is effective in hormone receptor (HR)–positive, HER2-negative advanced breast cancer (ABC) in both first-line (1L) and second-line (2L) settings in the real world, a multicentre observational study in Japan has shown.

In the treatment of bacterial vaginosis, dequalinium chloride is noninferior to metronidazole, with similarly high cure rates but better tolerability and fewer adverse events, according to a phase IV study.

Olanzapine appears to be just as effective as fosaprepitant, a neurokinin-1 receptor antagonist (NK1-RA), in controlling chemotherapy-induced nausea and vomiting (CINV) in patients with gynaecologic malignancies who were receiving carboplatin/paclitaxel chemotherapy every 3 weeks, a prospective study presented at SGO 2024 suggests. However, the former trumps the latter in terms of cost effectiveness.

Patient-reported outcomes (PROs) from the phase III MIRASOL trial underpin the potential of the antibody drug conjugate mirvetuximab soravtansine (MIRV) to improve health-related quality of life (HRQoL) in women with folate receptor-alpha positive platinum-resistant ovarian cancer (FRα-positive PROC) as opposed to investigator’s choice of chemotherapy.